These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 3876122)

  • 1. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.
    Mannucci PM; Lombardi R; Bader R; Vianello L; Federici AB; Solinas S; Mazzucconi MG; Mariani G
    Blood; 1985 Oct; 66(4):796-802. PubMed ID: 3876122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
    Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
    Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers.
    Mannucci PM; Lombardi R; Castaman G; Dent JA; Lattuada A; Rodeghiero F; Zimmerman TS
    Blood; 1988 Jan; 71(1):65-70. PubMed ID: 3257148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies.
    Mannucci PM; Lombardi R; Bader R; Horellou MH; Finazzi G; Besana C; Conard J; Samama M
    Blood; 1984 Sep; 64(3):614-21. PubMed ID: 6432075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.
    Castaman G; Lattuada A; Mannucci PM; Rodeghiero F
    Br J Haematol; 1995 Jan; 89(1):147-51. PubMed ID: 7833254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease.
    Mannucci PM; Lattuada A; Castaman G; Lombardi R; Colibretti ML; Ciavarella N; Rodeghiero F
    Blood; 1989 Nov; 74(7):2433-6. PubMed ID: 2804373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity.
    Federici AB; Mannucci PM; Lombardi R; Lattuada A; Colibretti ML; Dent JA; Zimmerman TS
    Am J Hematol; 1989 Dec; 32(4):287-93. PubMed ID: 2510503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.
    Casonato A; Pontara E; Sartorello F; Cattini MG; Sartori MT; Padrini R; Girolami A
    Blood; 2002 Jan; 99(1):180-4. PubMed ID: 11756169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
    Weiss HJ; Sussman II
    Blood; 1986 Jul; 68(1):149-56. PubMed ID: 3487353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma.
    Holmberg L; Berntorp E; Donnér M; Nilsson IM
    Blood; 1986 Sep; 68(3):668-72. PubMed ID: 3488775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups.
    Menache D; Aronson DL; Darr F; Montgomery RR; Gill JC; Kessler CM; Lusher JM; Phatak PD; Shapiro AD; Thompson AR; White GC
    Br J Haematol; 1996 Sep; 94(4):740-5. PubMed ID: 8826903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.